You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Inter-alpha Inhibitors in Hypoxic-Ischemic Brain Injury
SBC: PROTHERA BIOLOGICS, INC. Topic: 105Perinatal brain injury resulting in mental retardation and cerebral palsy is the most severe disability in children and affects 40-148 in preterm and 1–2/1000 in full term infants. This places a huge burden on society, emphasizing the critical need for improved prevention/treatment strategies to decrease perinatal brain injury. Hypothermia (HT) is the only FDA approved therapy to attenuate brain ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Point-of-care lateral flow immunoassay for diagnosis of pertussis
SBC: DXDISCOVERY INC Topic: NIAIDPertussis (Whooping cough) is a highly contagious, airborne disease that is rapidly re-emerging as a serious public health threat in the United States. Despite high vaccine coverage, annual reported cases in the U.S. have been increasing recently, with an average of 25,000 per year from 2010-2019. This is a level unseen since the early 1960s. Diagnosis of pertussis is challenging because its early ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.
SBC: TSRL, INC. Topic: NIAIDThe objective of this grant is the preclinical development of MRS-2541, a novel antibiotic structure targeting Gram+ bacteria by a new mechanism of action. MRS-2541 inhibits bacterial methionyl- tRNA synthetase required for bacterial protein synthesis, which is very different from its mammalian counterpart. MRS-2541 is the result of an arduous testing cascade of over 500 compounds requiring broad- ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Renal Therapeutic Angiogenesis Using the Novel Biologic ELP-VEGF
SBC: LEFLORE TECHNOLOGIES LLC Topic: 400Abstract.Chronic kidney disease (CKD) is a progressive disorder affecting almost 14% of the general population, and this disease has shown a relentless growth over the past 2 decades. Patients with CKD have higher rates of hospitalization, greater mortality, shorter life expectancy, and their healthcare costs are up to 5 times more expensive than non-CKD patients. Thus, treatments to slow, halt, o ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Introducing Neuroscience and Neurocomputation Concepts to High School Students using Brain-based Neurorobots
SBC: BACKYARD BRAINS INCORPORATED Topic: 106PROJECT SUMMARY Understanding the brain is a profound and fascinating challenge, captivating the scientific community and the public alike. The lack of effective treatment for most brain disorders makes training the next generation of neuroscientists, engineers and physicians a key concern. However, much neuroscience is perceived to be too difficult to be taught in school. To make neuroscience acc ...
SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
A Precision Medicine for Alcohol-Associated Liver Disease
SBC: GENETOBE INC Topic: 150ABSTRACT The goal of this study is to develop an RNAi-based genetic precision medicine to treat alcohol associated liver disease (AALD). AALD is a devastating health problem worldwide, accounts for the majority of alcohol-related mortality globally and is the second most indication for liver transplantation in the US. The current medical management for AALD remains limited, and no proven pathobiol ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy
SBC: STRYKAGEN CORPORATION Topic: 100Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with an incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The α7β1 integrin is a transmembrane linkage system in skeletal and card ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Addressing the wireless power problem: A low-power hybrid radio for neuroscience experiments
SBC: SPIKE NEURO LLC Topic: 101Project Summary Closed-loop stimulation is key to the study and treatment of neurological disorders. However, largely due to current wireless power demands, stimulation systems are restricted to wired connections, which impact natural behavior, induce motion artifacts, and limit complexity of study design. While a few wireless recording- only systems have been developed, the power demands of these ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
New approach for immune modulation against T1D
SBC: EVOQ THERAPEUTICS, INC. Topic: 200PROJECT SUMMARY/ABSTRACT Type 1 diabetes (T1D) is an autoimmune disease that affects 1 in 300 people by the age of 18 in the US. T1D is characterized by acute onset of hyperglycemia resulting from immune-mediated destruction of the insulin- producing β-cells in the pancreas. There is currently no cure for T1D and the disease requires constant management where the current standard of care/manageme ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A web-based platform for robust single-cell analysis, bulk data deconvolution and system-level analysis
SBC: ADVAITA CORP Topic: 400PROJECT SUMMARY Together with the ability to measure genome-wide expression of millions of individual cells, single-cell technologies have also brought the challenge of translating such data into a better understanding of the underlying biological phenomena. Existing computational methods and software for single-cell data analysis have critical limitations related to scalability, accuracy, usabili ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health